New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication

Abstract

Our data demonstrate that the well-characterised anti-tumour drug sorafenib efficiently blocks HCV replication in vitro. This novel effect of sorafenib should be further explored as an antiviral strategy for patients with chronic HCV infection.